SCHEMBL23994710

SCHEMBL23994710

COc1ncc(-c2cc(C3CC3)c3nc(C)cn3n2)c(OC)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 2/20 0.38
▸ PIK3CD O00329 1/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ EGFR P00533 1/20 0.38
▸ HCK P08631 1/20 0.38
▸ SRC P12931 1/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ PIK3CB P42338 1/20 0.38
▸ PIK3CG P48736 1/20 0.38
▸ EPHB4 P54760 1/20 0.38
▸ PRKDC P78527 1/20 0.38
▸ PI4KB Q9UBF8 1/20 0.38
▸ PPARD Q03181 1/20 0.37
▸ QPCT Q16769 1/20 0.35
▸ QPCTL Q9NXS2 1/20 0.35
▸ ACP1 P24666 1/20 0.35
▸ MDM2 Q00987 9/20 0.34
▸ TP53 P04637 5/20 0.34
▸ MDM4 O15151 3/20 0.34
▸ CYP1A2 P05177 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30224155 0.92 MTOR (0.38) MTORPIK3CDABL1EGFRHCK
SCHEMBL23992885 0.92 MTOR (0.38) MTORPIK3CDABL1EGFRHCK
SCHEMBL23994708 0.87 PPARD (0.38) MTORPIK3CDABL1EGFRHCK
SCHEMBL23994707 0.87 PPARD (0.38) MTORPIK3CDABL1EGFRHCK
SCHEMBL30224235 0.85 PPARD (0.37) MTORPIK3CDABL1EGFRHCK
SCHEMBL23994018 0.85 PPARD (0.37) MTORPIK3CDABL1EGFRHCK
SCHEMBL30224465 0.85 MTOR (0.38) MTORPIK3CDABL1EGFRHCK
SCHEMBL23991557 0.85 MTOR (0.38) MTORPIK3CDABL1EGFRHCK
SCHEMBL23993478 0.85 AKT1 (0.36) MTORPIK3CDABL1EGFRHCK
SCHEMBL30181563 0.85 AKT1 (0.36) MTORPIK3CDABL1EGFRHCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4422756-A1 CD73 COMPOUNDS GILEAD SCIENCES, INC. (US) 2024-09-04 — — EP disclosed
WO-2023077030-A1 CD73 COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-05-04 — — WO disclosed
EP-4143194-A1 CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-03-08 — — EP disclosed
US-20230039553-A1 CD73 COMPOUNDS GILEAD SCIENCES, INC. 2023-02-09 — — US disclosed
CN-115698009-A CD73 inhibiting 2,4-dioxopyrimidine compounds 吉利德科学公司 2023-02-03 — — CN disclosed
WO-2021222522-A1 CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS GILEAD SCIENCES, INC. (US) 2021-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039553-A1 CD73 COMPOUNDS ENTPD5, ENTPD1, NT5E MTOR 1667/4885PIK3CD 401/4885ABL1 1116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback